NCT01804686 2026-03-12
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
Clinical Trials
3 trialsNCT06271616 2025-12-26
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Mayo Clinic
Phase 2 Recruiting
NCT03790332 2025-10-21
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
Pharmacyclics LLC.
Phase 1/2 Completed